- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi, Miostat (carbachol) / Novartis
Bronchorelaxant effect of beclomethasone dipropionate in an ex vivo model of COPD exacerbation (TP-10 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3181;
BDP relaxed in a concentration-response manner hyperresponsive medium bronchi (Emax 74.89±20.77, pEC50 7.72±0.77) and small airways (Emax 61.79±14.62, pEC50 7.01±0.33) challenged with LPS and pre-contracted by carbachol. ConclusionsThe significant acute bronchorelaxant effect of BDP detected in a model of COPD exacerbation may explain the clinical efficacy of BDP/FF/GB FDC in improving lung function and protecting against exacerbation in COPD patients.
- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
Extrafine triple therapy shows improved efficacy compared to ICS/LABA in a mouse model of asthma (TP-10 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3172;
EF particle technology allows to reach and treat the whole bronchial tree, including small airways.Using a mouse model of HDM-induced asthma, the benefit of adding glycopyrronium bromide (GB) on top of beclomethasone dipropionate (BDP)/formoterol fumarate (FF) combination along with the effects of the EF versus non-extrafine (NEF) formulation were evaluated.The effect of EF BDP/FF/GB (triple) given as pMDI by inhalation at 3 doses (30/1.8/3.8, 10/0.6/1.3 and 3/0.2/0.4 µg/kg) was tested in comparison to EF BDP/FF and GB...MALDI-MSI revealed a more uniform distribution of EF formulation through the lung in comparison with NEF. These data suggest a better profile of EF triple compared to BDP/FF mainly on AHR and small airway remodeling as well as an improved efficacy of EF compared to NEF, thus supporting the added value of EF triple therapy for the treatment of asthma.
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Efficacy and safety of ICS/LABA/LAMA FDCs in COPD: a network meta-analysis (TP-9 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3152;
No significant differences were detected across the triple FDCs with respect to the efficacy and safety outcomes (Figure 1A). SUCRA ranked BUD/GLY/FOR the most effective FDC on exacerbation and TDI, and FF/UMEC/VI on FEV1 and SGRQ; no concerns raised on the safety profile, and the protection against mortality was related with the dose of ICS (Figure 1B).ConclusionsAll triple FDC are effective and safe in COPD regardless of the regimen of administration (twice daily vs. once daily), with no relevant difference on the risk of CV SAEs and pneumonia.
- |||||||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD (TP-9 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3145;
The primary outcome was the rate of moderate/severe exacerbations, defined by treatment with oral prednisolone and/or antibiotics. This first study of MART in COPD found that budesonide/formoterol MART is similarly effective as fluticasone/salmeterol fixed-dose therapy in moderate-severe COPD patients, at a lower daily inhaled corticosteroid dosage.
- |||||||||| dexamethasone / Generic mfg.
Utilization of corticosteroids among patients died with COVID 19: A single center experience from a resource poor setting (TP-5 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3075;
This first study of MART in COPD found that budesonide/formoterol MART is similarly effective as fluticasone/salmeterol fixed-dose therapy in moderate-severe COPD patients, at a lower daily inhaled corticosteroid dosage. Higher proportion of patients with bacterial co-infection were concomitantly treated with higher doses of corticosteroids,which could resulted in the adverse outcome.
- |||||||||| prednisolone / Generic mfg.
Comparison of resolution of Tuberculous pleural effusion on Anti – tubercular treatment with and without steroids : A one-year follow–up (TP-21 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2681;
2.To study radiological improvement post steroid treatment METHODOLOGY- 40 patients of TB pleural effusion were divided into two groups: one received ATT regimen and other group received oral prednisolone 0.75mg/kg in addition to ATT for 4 wks...Conclusions- We found that adjunctive prednisolone therapy was associated with decreased incidence of radiographic and functional sequelae in free-flowing type TPE patients. Resolution of clinical symptoms and effusion were significantly higher in steroid group as compared to control group.
- |||||||||| imatinib / Generic mfg.
Pharmacokinetics and pharmacodynamics of imatinib in COVID-19 patients (TP-20 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2667;
Css did associate significantly with P/F (β=-199,42; p-value=0.013) and O2lib (HR 0.75; p-value= 0.021), adjusted for sex, age, neutrophil-lymphocyte ratio, dexamethasone usage, AAG and baseline P/F-and WHO-score. Css did not significantly associate with WHO-score.
- |||||||||| dexamethasone / Generic mfg.
Impact of Dexamethasone Treatment on COVID-19 Pneumonia Mortality (TP-20 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2665;
The effectiveness of dexamethasone is difficult to assess in this post hoc real-world analysis. We speculate that the number and severity of underlying comorbidities are the main contributing factors to the individual outcome of COVID-19 pneumonia.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Real-life prospective study on tocilizumab in severe COVID-19 infection (TP-20 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2659;
The predominant variant at the time of this study was the Alpha variant, and so further investigation is required into its effectiveness in newer variants. Limitations include small sample size.
- |||||||||| dexamethasone / Generic mfg.
Inhaled beclomethasone in the treatment of early COVID-19: a double blind, placebo-controlled trial (TP-20 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2653;
The primary endpoint, progression to severe disease, was defined as a fall in oxygen saturation < 94% and any one or more of the following three treatment escalation steps: initiation of O2 therapy, initiation of dexamethasone, transfer to a higher-tier healthcare facility...InterpretationInhaled beclomethasone in early COVID-19 does not reduce progression to severe disease in a double blinded, placebo study. In light of this trial, findings of single blind or non-placebo controlled studies must be interpreted with caution.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
“Smart” inhalers: is there a role in the management of severe asthma? (TP-11 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2472;
Median FeNO and ACQ-6 score at baseline were 54 ppb and 3.08; and at 4 weeks were 38.5 ppb and 1.8 respectively. All patients had better asthma control at median follow up of 6 months.
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
Therapeutic stategies in hospitalised patients with SarsCov-2 hipoxemic pneumonia (8L) - Jun 22, 2022 - Abstract #ERS2022ERS_2264;
Objective – Evaluate the impact of real life use of remdesivir (RDV) as treatment for hypoxemic SarsCoV2 Pneumonia...In the RDV group, 97.1% patients were also receiving Dexamethasone (DEXA) and mean age was 69.7 (±14.4) years with 61.8% male prevalence, as opposed to the SoC group that registered 73.9 (±14.5) years and 49.7% male prevalence...Concerning the proposed outcomes: a) RDV patients had a mean Hospital Stay 4.25 days inferior than SOC subjects (p=0.002); b)The relative risk of death during hospital stay in the RDV group was 0.47 [0.38; 0.60] when compared to those in the SoC group; c) 9 subjects in the SoC group (0.03%) and 12 patients in the RDV group (0.014%) had secondary effects attributable to treatment drugs, all resolved with treatment interruption. Conclusion – The use of RDV with DEXA in SARSCoV-2 Hypoxemic Pneumonia significantly reduced mortality and hospital stay, and registered no significant side effects in a real life cohort of consecutively enrolled patients
- |||||||||| dexamethasone / Generic mfg.
Control of T cell-dependent steroid-resistant asthma model by several kinase inhibitors (TP-12 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_1069;
To analyze in vitro drug responsiveness, Th clones were cultured with antigen presenting cells and OVA in the presence of various concentrations of dexamethasone (DEX) and TKIs... Costimulatory signal is a promising target of TKIs to treat steroid-resistant asthma.
- |||||||||| prednisolone / Generic mfg.
Optimizing adrenal insufficiency screening in severe asthma patients on biologic therapy (TP-10 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_1037;
Measurement of baseline and 60 min serum cortisol levels alone were sufficiently able to identify all patients with AI; avoiding the need for an additional 30 min cortisol blood test. Reliance on the 30 min cortisol sample alone could led to an overdiagnosis of AI and prolonged exposure to OCS.
- |||||||||| fluticasone / Generic mfg.
Effects of inhaled corticoids on chronic bronchial infection by Pseudomonas aeruginosa in COPD patients (8F) - Jun 22, 2022 - Abstract #ERS2022ERS_782;
Aim: to investigate the expression of TLR2 and c-Jun in broncheoalveolar lavage (BAL) macrophages from COPD patients, infected with Pseudomonas aeruginosa (PA) and treated ex vivo with budesonide (B) or fluticasone (F)...Conclusions We observed that the TLR2 and c-Jun response to PA is blunted in BAL macrophages from COPD patients and, although appearing when co-treated with B or F, it remains inhibited in the COPD patients that are under ICS treatment. Although preliminary, these data suggest an effect of ICS in COPD patients thus inhibiting the inflammatory response though TLR2 and c-Jun, which potentially confers them a higher risk of pneumonia infection.
- |||||||||| fluticasone / Generic mfg.
Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients (8F) - Jun 22, 2022 - Abstract #ERS2022ERS_778;
A historical, observational study using patients ≥40 years, with ≥1 year of continuous medical data and who were commencing a fixed dose of extrafine beclometasone (ef-B), fine particle fluticasone (fp-F) or long-acting bronchodilators (LABD) was conducted... Reduced pneumonia risk in COPD patients commencing ef-B is an important observation, particularly for individuals at high risk due to demographic and clinical factors.
- |||||||||| methylprednisolone oral / Generic mfg.
Methylprednisolone in the treatment of post-COVID-19 Interstitial Lung Disease (STERCOV-ILD) (TP-24 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_585;
Patients with a radiological response in steroid group tend to be higher than control group, but not statistically significant (61.1 % vs 51.1 %, p=0.159). The increase in oxygen saturation, FVC, and 6-minute walking distance were significantly higher in the steroid group compared to the control.
- |||||||||| dexamethasone / Generic mfg.
New physiomimetic model for ARDS in vitro studies (TP-8 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_280;
Rat primary lung alveolar epithelial cells (AECs) were cultured on top of the hydrogels and subjected to a LPS challenge for 16h and to dexamethasone treatment for other 16h...CONCLUSIONSResults indicate that the developed physiomimetic model of ARDS-on-a-chip responds to a LPS challenge and partially recover the level of cytokines after anti-inflammatory drug treatment. Thus, the developed model opens the door for further in vitro research in the development of novel therapeutic strategies for ARDS treatment.
- |||||||||| dexamethasone / Generic mfg.
COVID-19 and comorbidity: possible complications of the complex pharmacotherapy (TP-1 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_148;
When OP is present length of stay increases significantly which inevitably has more impact in quality of life. in pts with COVID-19 and comorbidity, it is necessary to adjust the doses of drugs and avoid polypharmacy to reduce the risk of side effects from adverse drug interactions.
- |||||||||| dexamethasone / Generic mfg., ropivacaine / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Surgery: COESPINE: Comparison Erect Spine in Cardiac Surgery (clinicaltrials.gov) - Jun 21, 2022
P3, N=40, Recruiting,
N=119 --> 277 Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Feb 2023
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: PROUD Study - Preventing Opioid Use Disorders (clinicaltrials.gov) - Jun 21, 2022
P4, N=170, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Feb 2023 Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Dec 2022
- |||||||||| belrestotug (EOS-448) / iTeos, GSK
Enrollment open, Combination therapy: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 21, 2022
P1/2, N=162, Recruiting,
Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- |||||||||| dexamethasone / Generic mfg.
Journal: A three-dimensional (3D), serum-free, Collagen Type I system for chondrogenesis of canine bone marrow-derived multipotent stromal cells (cMSCs). (Pubmed Central) - Jun 19, 2022
In the presence of dexamethasone and transforming growth factor-β3 (TGF-β3), both bone morphogenic protein-2 (BMP-2) and basic fibroblast growth factor (bFGF) generated larger chondrogenic constructs, although BMP-2 was required to achieve histologic characteristics of chondrocytes...Finally, TUNEL staining was positive in constructs lacking BMP-2 or bFGF. In conclusion, the 3D, serum-free, Collagen Type-I assay described herein proved useful in assessing cMSC differentiation and will serve as a productive system to characterize cMSCs or to fabricate tissue engineering constructs for clinical use.
- |||||||||| dexamethasone injection / Generic mfg., amoxycillin/clavulanate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Journal: Acute inhalation lung injury secondary to zinc and copper aspiration from food contact dust. (Pubmed Central) - Jun 19, 2022
He was treated with intravenous methylprednisolone, followed by a weaning dose of oral prednisolone over 14 days.He required oxygen therapy for 9 days and remained in hospital for 11 days. Outpatient follow-up, 24 days after the inhalation took place was reassuring with the child showing no signs of abnormal respiratory symptoms.
- |||||||||| Miostat (carbachol) / Novartis
Preclinical, Journal: Functional and morphologic dysfunctions in the airways of rats submitted to an experimental model of obesity-exacerbated asthma. (Pubmed Central) - Jun 19, 2022
Animals were divided into groups: control (Ctrl), obese (Ob), asthmatic (Asth), obese asthmatic (Ob + Asth) and obese asthmatic treated with dexamethasone (Ob + Asth + Dexa), and in vivo and in vitro functional and morphological parameters were measured...In isolated tracheas, carbachol showed an increase in contractile efficacy in the Ob, Ob + Asth and Ob + Asth + Dexa, but mostly on Ob + Asth...An obesity-exacerbated asthma model was successfully established. Therefore, this model allows further molecular investigations and the search for new therapies for the treatment and relief of symptoms of patients with obesity-induced resistant asthma.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Beneficial Effect of HS-Releasing Molecules in an In Vitro Model of Sarcopenia: Relevance of Glucoraphanin. (Pubmed Central) - Jun 19, 2022
Here, in an in vitro model of sarcopenia based on damage induced by dexamethasone (DEX, 1 μM, 48 h treatment) in C2C12-derived myotubes, we investigated the protective potential of exogenous and endogenous sources of HS, i.e., glucoraphanin (30 μM), L-cysteine (150 μM), and 3-mercaptopyruvate (150 μM)...In conclusion, in an in vitro model of sarcopenia, an impairment in CBS/CSE/HS signalling occurs, whereas glucoraphanin, a natural HS-releasing molecule, appears more effective for preventing the SKM damage. Therefore, glucoraphanin supplementation could be an innovative therapeutic approach in the management of sarcopenia.
- |||||||||| bardoxolone methyl (RTA 402) / Kyowa Kirin, Reata
Preclinical, Journal: Novel Epoxides of Soloxolone Methyl: An Effect of the Formation of Oxirane Ring and Stereoisomerism on Cytotoxic Profile, Anti-Metastatic and Anti-Inflammatory Activities In Vitro and In Vivo. (Pubmed Central) - Jun 19, 2022
It was found that novel SM epoxides induced the death of tumor cells at low micromolar concentrations (IC = 0.7-4.1 µM) via the induction of mitochondrial-mediated apoptosis, reinforced intracellular accumulation of doxorubicin in B16 melanoma cells, probably by direct interaction with key drug efflux pumps (P-glycoprotein, MRP1, MXR1), and the suppressed pro-metastatic phenotype of B16 cells, effectively inhibiting their metastasis in a murine model...Furthermore, the effect of the stereoisomerism of SM epoxides on the mentioned bioactivities and toxic profiles of these compounds in vivo were evaluated. Considering the comparable antitumor and anti-inflammatory effects of SM epoxides with SM and reference drugs (dacarbazine, dexamethasone), αO-SM and βO-SM can be considered novel promising antitumor and anti-inflammatory drug candidates.
|
